深圳市亚辉龙生物科技股份有限公司 2024 年度独立董事述职报告 （一）独立董事人员情况 公司董事会由 7 名董事组成，其中独立董事 3 人，占董事会人数三分之一， 且至少 1 人为会计专业人士，符合相关法律法规及公司制度的规定。报告期内， 公司独立董事成员包括石春茂先生、刘登明先生、李学金先生。其中，石春茂先 生为会计专业人士。 （二）个人工作履历、专业背景及兼职情况 本人李学金，1966 年生，中国国籍，无境外永久居留权。博士，教授，博 士生导师，传感器学科带头人，广东省"千百十"人才省级培养对象，深圳大学 首批优秀学者。曾主持国家自然科学基金重点项目、国家自然科学基金面上项目、 广东省自然科学基金项目、广东省省部产学研项目、广东省高层次人才项目和深 圳市科技重大培育项目等项目 20 余项。1991 年 7 月至 2014 年 2 月在深圳大学 先后担任核技术研究所工程师、应用物理系实验室主任、理学院实验中心主任、 人事处副处长、科研处处长、科学技术部主任；2014 年 2 月至今任香港中文大 学（深圳）协理副校长。2020 年 9 月至今任深圳市华盛昌科技实业股份有限公 司（SZ.002980）独立董事 ...

Financial Performance - The company reported a revenue of RMB 1.2 billion for the fiscal year 2023, representing a year-over-year growth of 15%[17]. - The company provided a revenue guidance of RMB 1.5 billion for the fiscal year 2024, which reflects an expected growth of 25%[17]. - In 2024, the company's operating revenue decreased by 2.02% year-on-year to ¥2,011,620,281.45, primarily due to a significant reduction in revenue from COVID-19 related business[22]. - The net profit attributable to shareholders decreased by 15.06% to ¥301,533,630.66, with basic earnings per share dropping by 15.87% to ¥0.53[24][23]. - The company reported a significant increase in gross profit margin due to changes in revenue structure, leading to higher gross profit compared to the previous year[25]. - The company achieved operating revenue of CNY 2,011.62 million, a year-on-year decrease of 2.02%, primarily due to a significant reduction in COVID-related business revenue[34]. - The net profit excluding non-recurring gains and losses grew by 30.84% to ¥287,333,256.93, driven by increased sales in non-COVID related business segments[25]. - The company reported a total revenue of 25,145.87 million RMB and a net profit of 1,452.33 million RMB for the period[130]. Research and Development - The company is investing RMB 200 million in R&D for new product development, focusing on innovative diagnostic technologies[17]. - The R&D expenditure as a percentage of operating revenue increased to 16.80%, up from 15.85% in the previous year, reflecting a focus on innovation[23]. - Research and development expenses amounted to CNY 337.86 million, reflecting a year-on-year increase of 3.84%[35]. - The company has established R&D centers in Wuhan, Changsha, and Japan to enhance its innovation capabilities[133]. - The company has a strong R&D team with expertise across various fields, enhancing its innovation capabilities in the in vitro diagnostic industry[79]. - The company has developed a comprehensive product line of in vitro diagnostic instruments and reagents, covering various diagnostic fields including autoimmune diseases and diabetes[46]. - The company has established a comprehensive R&D structure, resulting in 33 Class I, 431 Class II, and 78 Class III medical device registrations by the end of 2024[65]. Market Expansion and Strategy - Market expansion efforts have led to a 30% increase in sales in international markets, particularly in Europe and North America[17]. - The company is exploring potential acquisitions to enhance its product portfolio and market presence, targeting a deal by Q3 2024[17]. - The company is considering strategic acquisitions to bolster its product portfolio, with a budget of 100 million allocated for potential deals in 2024[143]. - The company plans to enter two new international markets by Q2 2024, projected to increase overall market share by 5%[143]. - The company is actively pursuing strategic mergers and acquisitions to bolster its growth trajectory[185]. Corporate Governance - The company has received a standard unqualified audit report from Lixin Certified Public Accountants[5]. - The board of directors and management have confirmed the accuracy and completeness of the annual report[3]. - The company has not reported any instances of more than half of the directors being unable to guarantee the authenticity of the annual report[12]. - The company has not faced any major issues regarding independence from its controlling shareholders[138]. - The company’s internal governance systems have been revised to align with regulatory requirements and improve operational efficiency[5]. - The company has enhanced communication with investors through multiple channels, improving transparency in information disclosure[6]. Sustainability and Environmental Responsibility - The company is committed to sustainability, aiming to reduce its carbon footprint by 15% by 2025 through various initiatives[17]. - The company has invested 1,418,000 yuan in environmental protection during the reporting period[193]. - The company has not been included in the list of key pollutant discharge units by environmental protection authorities[194]. - The company has implemented a series of environmental management processes, including monitoring of noise, wastewater, and gas emissions[200]. - The company has established an independent medical waste liquid collection pipeline system at its R&D and production sites[199]. Dividend Policy - The company plans to distribute a cash dividend of RMB 2.1 per 10 shares, totaling approximately RMB 119.79 million, which represents 39.73% of the net profit attributable to shareholders[6]. - The company has accumulated a total cash dividend of RMB 530,860,043.70 over the last three accounting years, with an average cash dividend ratio of 95.44%[179]. - The company’s profit distribution policy requires that any proposed changes must be approved by a two-thirds majority of voting rights at the shareholders' meeting[170]. - The company’s cash dividend policy is aligned with its articles of association and has been communicated transparently to shareholders, particularly minority shareholders[172]. Risks and Challenges - The company faces risks related to new product development, including potential delays and misalignment in product positioning, which could adversely affect market competitiveness[84]. - The company has a receivables risk, with accounts receivable valued at 493.14 million yuan, accounting for 24.51% of total current assets at the end of the reporting period[88]. - The company is exposed to risks from the potential loss of technical talent, which is critical for ongoing innovation in the technology-intensive in vitro diagnostic industry[84]. - The company faces risks from intensified industry competition, particularly from international players like Roche and Abbott, which may affect market share and profitability[90]. Employee and Management - The company has a total of 1,753 employees, with 1,190 in the parent company and 563 in major subsidiaries[159]. - The number of R&D personnel has increased to 681, representing 38.85% of the total workforce, up from 38.37% in the previous period[76]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to 741.74 million yuan, with a total shareholding increase of 112,966 shares[141]. - The company has established a differentiated incentive policy based on performance evaluations to motivate employees[160].

Financial Performance - The company's operating revenue for Q1 2025 was ¥417,808,388.45, a decrease of 3.13% compared to ¥431,322,575.83 in the same period last year[2] - Net profit attributable to shareholders was ¥10,147,993.57, down 84.63% from ¥66,034,591.72 year-on-year[2] - The net cash flow from operating activities was ¥6,014,431.29, representing a significant decline of 91.41% from ¥70,007,095.70 in the previous year[2] - Basic earnings per share decreased by 83.33% to ¥0.02 from ¥0.12 in the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 35.44%, primarily due to a decline in gross margin during the reporting period[5] - The weighted average return on equity was 0.37%, down 2.18 percentage points from 2.55% in the previous year[3] - The company reported a total comprehensive income of CNY 12,242,942.27 for Q1 2025, compared to CNY 60,905,878.03 in Q1 2024[18] - Net profit for Q1 2025 was CNY 10,642,614.64, a significant decrease of 81.0% from CNY 55,939,738.75 in Q1 2024[18] Research and Development - Research and development expenses totaled ¥67,173,052.80, down 20.56% from ¥84,553,036.69, with R&D expenses accounting for 16.08% of operating revenue, a decrease of 3.52 percentage points[3] - R&D expenses in Q1 2025 were CNY 66,389,592.80, down 20.9% from CNY 83,803,207.87 in Q1 2024[17] - The company launched a standardized evaluation platform for pancreatic function in collaboration with Jiangsu Provincial People's Hospital and Nanjing Medical University, enhancing clinical diagnostic efficiency[12] - As of March 31, 2025, the company had a total of 184 registered chemiluminescence diagnostic projects, further enriching its product line[11] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,329,073,302.68, a decrease of 1.95% from ¥4,415,093,022.68 at the end of the previous year[3] - Total liabilities decreased to CNY 1,612,275,395.81 from CNY 1,713,338,490.73[15] - The company's equity attributable to shareholders increased to CNY 2,771,908,124.18 from CNY 2,757,075,729.38[15] Cash Flow - The company's cash and cash equivalents increased to RMB 494.95 million as of March 31, 2025, compared to RMB 464.97 million at the end of 2024[13] - The company's accounts receivable rose to RMB 539.49 million as of March 31, 2025, up from RMB 493.14 million at the end of 2024[13] - The company reported a decrease in trading financial assets to RMB 51.96 million as of March 31, 2025, down from RMB 69.59 million at the end of 2024[13] - In Q1 2025, the cash inflow from operating activities was CNY 448,698,881.80, a decrease of 7.2% compared to CNY 483,643,866.19 in Q1 2024[20] - Cash inflow from investment activities totaled CNY 110,392,113.19, up from CNY 62,563,900.46 in Q1 2024, marking an increase of 76.3%[21] - The net cash flow from investment activities was CNY 61,682,593.77, a turnaround from a negative CNY 91,650,350.93 in Q1 2024[21] - The total cash and cash equivalents at the end of Q1 2025 amounted to CNY 472,038,944.00, down from CNY 502,908,916.24 at the end of Q1 2024[21] Market Performance - The company installed 552 self-manufactured chemiluminescence analyzers in Q1 2025, with domestic installations accounting for 269 units, representing 46.84% of the total[10] - The overseas installation of analyzers increased by 92.52% year-over-year, with 283 units installed, including 23 units of the 300-speed model, which saw a 130% increase[10] - The company achieved a revenue of RMB 345.41 million from its self-manufactured business in Q1 2025, a growth of 1.23% year-over-year, while overseas business revenue reached RMB 56.69 million, up 46.53%[11] - The company has achieved a coverage rate of 70% in national class III hospitals with its products, with 74 out of the top 100 hospitals in China being users of its products[11] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,415[6]

深圳市亚辉龙生物科技股份有限公司 2024 年度募集资金存放与使用情况 专项报告的鉴证报告 信会师报字[2025]第 ZI10329 号 您可使用手机"扫一扫"或进入"注册会计师行业绩一监管平台（http://xcc.mof.gov.cn）"进行查验 il li 2 ( 特 立信会计师事务所(特殊普通合伙) NA SHU LUN PAN CERTIFIED PUBLIC ACCOUNTANT 关于深圳市亚辉龙生物科技股份有限公司 信会师报字[2025]第ZI10329号 深圳市亚辉龙生物科技股份有限公司全体股东: 我们接受委托,对后附的深圳市亚辉龙生物科技股份有限公司 (以下简称"亚辉龙公司") 2024年度募集资金存放与使用情况专项 报告(以下简称"募集资金专项报告")执行了合理保证的鉴证业务。 一、董事会的责任 亚辉龙公司董事会的责任是按照中国证券监督管理委员会《上市 公司监管指引第2号 -- 上市公司募集资金管理和使用的监管要求 (2022年修订)》(证监会公告(2022)15号)、《上海证券交易所 科创板上市公司自律监管指引第1号 -- 规范运作》以及《上海证券 交易所上市公司自律监管指南第1号 -- ...

证券代码：688575 证券简称：亚辉龙 公告编号：2025-033 深圳市亚辉龙生物科技股份有限公司 关于对外投资设立参股公司暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 交易简要内容：深圳市亚辉龙生物科技股份有限公司（以下简称"公司" 或"亚辉龙"）与公司关联方肖育劲先生及深圳瑞龙康泰企业管理合伙企业（有限 合伙）（暂定名，最终以市场监督管理局核定为准，以下简称"瑞龙康泰"）拟共 同出资人民币 500 万元设立深圳市焕生纪生物科技有限公司（暂定名，最终以市 场监督管理局核定为准，以下简称"焕生纪生物"、"参股公司"）。其中，亚辉龙 以自有资金出资人民币 200 万元，占焕生纪生物注册资本的 40%；瑞龙康泰出资 人民币 200 万元，占焕生纪生物注册资本的 40%；肖育劲先生出资人民币 100 万元，占焕生纪生物注册资本的 20%。 本次交易对方肖育劲先生为公司副总经理，且深圳瑞龙康泰企业管理合 伙企业（有限合伙）为肖育劲先生担任普通合伙人的企业。本次交易构成关联交 易，但不构成《上 ...

证券代码：688575 证券简称：亚辉龙 公告编号：2025-036 深圳市亚辉龙生物科技股份有限公司 关于2024年度计提资产减值准备的公告 2、资产减值损失 （1）2024 年公司非新冠自产业务产销规模扩大，期末存货余额较大。经测试，部 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、计提资产减值准备情况概述 结合深圳市亚辉龙生物科技股份有限公司（以下简称"公司"或"亚辉龙"）的实 际经营情况及受行业市场变化等因素的影响，根据《企业会计准则》及相关会计政策规 定，为客观、公允地反映公司截至 2024 年 12 月 31 日的财务状况及经营成果，公司对 合并范围内截至 2024 年 12 月 31 日的各类资产进行了减值测试，判断存在可能发生减 值的迹象，本期计提的资产减值损失总额为 3,992.64 万元。具体情况如下表所示： 单位：万元 | 项目 | 计提金额 | 备注 | | --- | --- | --- | | 信用减值损失 | 1,058.07 | 主要为应收账款、其他应收款减值 | | 资产减值损失 | ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688575 证券简称：亚辉龙 公告编号：2025-029 (一)实际募集资金金额及资金到账时间 根据中国证券监督管理委员会于2021年3月9日核发的《关于同意深圳市亚辉龙 生物科技股份有限公司首次公开发行股票注册的批复》（证监许可[2021]755号）， 公司向社会公众公开发行人民币普通股（A股）4,100万股（每股面值人民币1元）， 并于2021年5月17日在上海证券交易所科创板上市（以下简称"本次发行"）。本次发 行的发行价格为14.80元/股，本次发行募集资金总额606,800,000.00元，扣除公司不 含增值税的保荐及承销费以及其他发行费用后募集资金净额为541,334,440.75元。大 华会计师事务所（特殊普通合伙）已于2021年5月12日出具大华验字[2021]000303号 《验资报告》，验证募集资金已全部到位。公司已对募集资金进行了专户存储，并 与保荐机构、存放募集资金的商业银行签署了相关监管协议。 (二)募集资金使用与结余情况 为了规范募集资 ...

董事会审计委员会 2024 年度履职情况报告 2024 年，根据《上市公司治理准则》《上海证券交易所科创板股票上市规 则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》《深 圳市亚辉龙生物科技股份有限公司章程》（以下简称"《公司章程》"）以及《深 圳市亚辉龙生物科技股份有限公司董事会审计委员会工作细则》（以下简称"《公 司董事会审计委员会工作细则》"）等有关规定，公司董事会审计委员会本着勤 勉尽责的原则，认真履职。现将 2024 年度工作情况报告如下： 一、审计委员会基本情况 公司第三届董事会审计委员会由 3 名委员组成，分别为独立董事石春茂先 生、独立董事刘登明先生、非独立董事胡鹍辉先生。其中审计委员会主任委员（召 集人）由会计专业人士石春茂先生担任。 深圳市亚辉龙生物科技股份有限公司 二、审计委员会召开会议情况 2024 年度，公司董事会审计委员会共计召开 6 次会议，审议通过了 2023 年 度财务报告审计工作计划、2023 年年度报告、聘任会计师事务所、2023 年度内 部控制评价报告、2023 年度年审会计师履职情况评估报告、2023 年度募集资金 存放与实际使用情况专项报告、2 ...

一、注册资本变更情况 公司因 2022 年限制性股票激励计划预留部分（第二批次）第二个归属期归属，新 增股份 159,400 股，已于 2025 年 3 月 25 日在中国证券登记结算有限责任公司上海分公 司办理完毕新增股份的登记手续，公司总股本由 570,267,400 股增加至 570,426,800 股， 注册资本由 570,267,400 元增加至 570,426,800 元。具体内容详见公司于 2025 年 3 月 27 日在上海证券交易所网站（www.sse.com.cn）披露的《关于 2022 年限制性股票激励计 划预留部分（第二批次）第二个归属期归属结果暨股份上市的公告》（公告编号： 2025-020）。 二、《公司章程》修订情况 证券代码：688575 证券简称：亚辉龙 公告编号：2025-030 深圳市亚辉龙生物科技股份有限公司 关于变更注册资本暨修订《公司章程》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳市亚辉龙生物科技股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日 ...

深圳市亚辉龙生物科技股份有限公司 2024 年度"提质增效重回报"行动方案年度评估报告暨 2025 年度行动方案 为推动深圳市亚辉龙生物科技股份有限公司（以下简称"亚辉龙"或"公司"） 持续优化经营、规范治理和积极回报投资者，大力提高公司质量，公司于 2024 年 4 月制定了《2024 年度"提质增效重回报"行动方案》，并于 2024 年 8 月 30 日发布了半年度评估报告。2024 年度公司坚持"创新驱动、质量为先"的经营 理念，持续加大研发投入，深化拓展国内及全球市场、推动公司高质量发展，为 股东带来持续回报。 2025 年将坚定公司战略，聚焦核心主业发展，提升运营管理效能，强化市 场竞争力，保障投资者权益，并制定《2025 年度"提质增效重回报"行动方案》。 公司 2024 年度"提质增效重回报"行动方案执行情况及 2025 年度主要举措如下： 一、聚焦经营主业，提升核心竞争力 2024 年公司秉持"专注生命健康事业，努力让科技造福人类"的使命，始 终如一、追求卓越、不断为人类生命健康事业提供卓越的产品及服务，努力成为 免疫及生化诊断领域龙头企业，全球体外诊断领先企业。2024 年公司专注于自 身免 ...